Bain Capital Life Sciences Investors, LLC
Bain Capital Life Sciences Investors, LLC's purchase track record
How the stock did after each of Bain Capital Life Sciences Investors, LLC's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/20/2026 | KLRA | $25.00M | -27.2% | pending | — |
| 2/19/2025 | SLDB | $4.03M | -58.3% | -12.5% | +4.1% |
| 1/8/2025 | OLMA | $1.73M | -45.2% | -13.2% | +5.8% |
| 2/12/2024 | KYTX | $9.90M | -51.1% | -78.2% | +6.4% |
| 5/25/2023 | ANNX | $640K | +40.9% | +29.5% | +9.8% |
| 12/8/2021 | XLO | $410K | -22.5% | -69.6% | -12.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 24, 2026
Kailera Therapeutics faces scrutiny on weight loss differentiation. Recent analysis highlights the need for Kailera to clearly differentiate its weight loss drug from existing GLP-1 competitors. The stock is currently trading near its support level, reflecting cautious sentiment as investors await concrete progress on the company's obesity treatment pipeline.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
SLDB Featured in After-Market Movers List. Solid Biosciences was included in a Benzinga list of healthcare stocks moving in Friday's after-market session. The stock is currently trading near its 52-week low, with an RSI of 20.5 indicating oversold conditions. Analysts maintain an average price target of $18.62, which is significantly higher than the current trading range.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
OLMA Joins 12 Healthcare Stocks Moving in Pre-Market. OLMA was among 12 healthcare stocks that moved in Wednesday's pre‑market session, signaling early interest from traders. The move comes while the stock sits near its 52‑week low and a low RSI of 19.1, suggesting it may be oversold. This early activity could reflect new market sentiment or a reaction to broader healthcare sector dynamics.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Kyverna Reports Positive One-Year Data for Miv-cel Trials. Kyverna Therapeutics disclosed one‑year data from its Miv‑cel trials in stiff person syndrome and generalized myasthenia gravis, showing durable responses and a favorable safety profile. The CEO noted that the high disease burden supports a premium pricing strategy. These results reinforce the potential of a single‑dose therapy to reduce long‑term treatment burden.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
ANNX Listed Among Health Care Stocks Moving Pre-Market. Annexon Inc. was included in a list of health care stocks showing movement during Friday's pre-market session. The stock is currently trading near its 52-week low, with technical signals indicating a breakdown below the Bollinger Bands. Analysts maintain a wide range of price targets, reflecting uncertainty about the company's future performance.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Xilio Therapeutics appoints Yariv J. Houvras as Chief Medical Officer. Xilio Therapeutics announced that Dr. Yariv J. Houvras, M.D., Ph.D., will serve as its new Chief Medical Officer. The appointment adds experienced clinical leadership to the company as it advances its therapeutic pipeline. This change comes while the stock is trading near the top of its 52‑week range, suggesting market attention to the leadership update.
Transaction History
| HTFL | ▼ Sell | Open Market | 892,533 | $26.0M | 4/30/2026 | View on chart |
| HTFL | ▼ Sell | Open Market | 56,224 | $1.7M | 4/30/2026 | View on chart |
| HTFL | ▼ Sell | Open Market | 797,133 | $23.4M | 4/29/2026 | View on chart |
| HTFL | ▼ Sell | Open Market | 254,110 | $7.8M | 4/28/2026 | View on chart |
| KLRA | ▼ Sell | Other | 4,145,768 | — | 4/20/2026 | View on chart |
| KLRA | ▼ Sell | Other | 16,875,000 | — | 4/20/2026 | View on chart |
| KLRA | ▲ Buy | Open Market | 1,562,500 | $25.0M | 4/20/2026 | View on chart |
| HTFL | ▼ Sell | Open Market | 2,000,000 | $56.1M | 2/4/2026 | View on chart |
| HTFL | ▼ Sell | Other | 433,924 | $6.6M | 8/11/2025 | View on chart |
| HTFL | ▼ Sell | Other | 12,014,234 | — | 8/11/2025 | View on chart |
| SLDB | ▲ Buy | Open Market | 1,000,000 | $4.0M | 2/19/2025 | View on chart |
| OLMA | ▼ Sell | Other | 3,500,000 | — | 1/10/2025 | View on chart |
| OLMA | ▲ Buy | Open Market | 300,000 | $1.7M | 1/8/2025 | View on chart |
| KYTX | ▼ Sell | Other | 2,713,868 | — | 2/12/2024 | View on chart |
| KYTX | ▲ Buy | Open Market | 450,000 | $9.9M | 2/12/2024 | View on chart |
| SLDB | ▲ Buy | Grant | 904,160 | $5.0M | 1/11/2024 | View on chart |
| ANNX | ▲ Buy | Open Market | 300,000 | $640K | 5/25/2023 | View on chart |
| XLO | ▲ Buy | Open Market | 21,812 | $209K | 12/10/2021 | View on chart |
| XLO | ▲ Buy | Open Market | 3,188 | $33K | 12/10/2021 | View on chart |
| XLO | ▲ Buy | Open Market | 4,011 | $39K | 12/9/2021 | View on chart |
| XLO | ▲ Buy | Open Market | 13,458 | $129K | 12/8/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Heartflow featured in AI healthcare stock roundup
Heartflow was included in a recent Yahoo Finance article highlighting top AI healthcare stocks alongside Pfizer and another company. This mention places the firm in the conversation regarding artificial intelligence applications in the medical sector. The stock currently trades within its 52-week range, with analysts maintaining an average price target of $46.00.
Heartflow featured in AI healthcare stock roundup. Heartflow was included in a recent Yahoo Finance article highlighting top AI healthcare stocks alongside Pfizer and another company. This mention places the firm in the conversation regarding artificial intelligence applications in the medical sector. The stock currently trades within its 52-week range, with analysts maintaining an average price target of $46.00.